TriGemX Bio And TCGX Acquisition File Form S-4; Expect To Close Combination In Q1 2027 And Trade On Nasdaq Under Ticker Symbol 'TGEM'
TriGemX Bio, Inc. ("TriGemX Bio"), a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, and TCGX Acquisition Corp. (NASDAQ:TCGX) ("TCGX"), a
Two companies are joining together to make one bigger company. When they finish the deal next year, you can watch for whether their migraine medicine works and if investors stay interested.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.